期刊文献+

黄嘌呤氧化还原酶表达对鼻咽癌预后的影响

Expression of xanthine oxidoreductase and its value in prognosis of patients with nasopharyngeal carcinoma
下载PDF
导出
摘要 目的探讨黄嘌呤氧化还原酶(XOR)在鼻咽癌患者中的表达情况,并探讨其对患者预后的影响。方法采用免疫组化法检测90例鼻咽癌患者活检标本的XOR表达情况,并分析其与预后之间的关系。结果鼻咽癌组织XOR阳性表达率为52.2%,在不同病理类型间表达差异无统计学意义。XOR表达TNM分期间存在密切关系。XOR阳性表达患者5年生存率为42.6%,阴性表达者为65.2%,两者比较差异有统计学意义(P<0.05)。结论 XOR可以作为评价鼻咽癌患者预后的参考依据之一。 Objective To investigate the expression of xanthine oxidoreductase (XOR) and its value in prognosisof patients with nasopharyngeal carcinoma. Methods Immunohistochemical staining was performed on the biopsy specimen from 90 patients with nasopharyngeal carcinoma. The prognostic value of the XOR immunostaing was evaluated. Results Positive XOR expression was observed in 52. 2% of cases, and there was no signicant difference between pathological manifestations of cancer. The expression of XOR was related to tumor TNM stage. The cumulative 5-years survival rate in patients with positive XOR expression was 42. 6%, compared with 65.2% in those with negatice expression. Conclusion Expression of XOR may be a new prognostic marker for patients with nasopharyngeal carcinoma.
出处 《安徽医科大学学报》 CAS 北大核心 2013年第5期496-498,共3页 Acta Universitatis Medicinalis Anhui
基金 安徽省教育厅自然科学基金(编号:KJ2012Z147)
关键词 鼻咽癌 黄嘌呤氧化酶 预后 nasopharyngeal carcinoma xanthine oxidoreductase prognosis
  • 相关文献

参考文献15

  • 1朱大高,钱立庭,张红雁,马军,刘云琴,朱蕾蕾,程勋全.164例鼻咽癌放射治疗疗效和预后因素分析[J].安徽医科大学学报,2010,45(4):535-538. 被引量:10
  • 2邓伟,黄天壬,陈万青,张思维,郑荣寿,利基林.中国2003—2007年鼻咽癌发病与死亡分析[J].肿瘤,2012,32(3):189-193. 被引量:94
  • 3Agarwal A, Banerjee A, Banerjee U C. Xanthine oxidoreductase:a journey from purine metabolism to cardiovascular excitation-con-txaction coupling[ J]. Crit Rev Biotechnol, 2011,31(3) : 264 -80.
  • 4Boueiz A, Damarla M, Hassoun P M. Xanthine oxidoreductase inrespiratory and cardiovascular disorders [ J ]. Am J Physiol LungCell Mol Physiol,2008 , 294(5) : L830 -40.
  • 5Sulikowski T, Domanski L,Ciechanowski K, et al. Effect of trim-etazidine on xanthine oxidoreductase expression in rat kidney withischemia-repeifusion injury[ J]. Arch Med Res, 2008,39(4):459 -62.
  • 6Linder N, Butzow R, Lassus H, et al. Decreased xanthine oxi-doreductase (XOR) is associated with a worse prognosis in pa-tients with serous ovarian carcinoma [ J ] . Gynecol Oncol,2012,124(2) : 311 -8.
  • 7Linder N, Haglund C, Lundin M, et al. Decreased xanthine oxi-doreductase is a predictor of poor prognosis in early-stage gastriccancer[J]. J Clin Pathol, 2006,59(9) : 965 -71.
  • 8Linder N, Martelin E, Lundin M, et al. Xanthine oxidoreductase-clinical significance in colorectal cancer and in vitro expression ofthe protein in human colon cancer cells[ J] . Eur J Cancer, 2009,45(4): 648 -55.
  • 9Kim A W, Batus M, Myint R, et al. Prognostic value of xanthineoxidoreductase expression in patients with non-small cell lungcancer[ J]. Lung Cancer, 2011,71(2) : 186 -90.
  • 10Konno H, Minamiya Y, Saito H, et al. Acquired xanthine dehy-drogenase expression shortens survival in patients with resected ad-enocarcinoma of lung[ J]. Tumour Biol, 2012, 33(5): 1727 -32.

二级参考文献46

共引文献362

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部